Indigo
Geoffrey von Maltzahn is a distinguished General Partner at Flagship Pioneering, where Geoffrey has been since 2009, contributing to the development of numerous life sciences companies aimed at transforming human health and sustainability. As the Founding CEO and Executive Chairman at Quotient Therapeutics, and the Founding CEO and Chairman of the Board at Tessera Therapeutics, von Maltzahn is at the forefront of innovative biotechnology initiatives, including gene writing and somatic genomics. Geoffrey also holds leadership roles at several other companies, such as Generate Biomedicines, Indigo, Sana Biotechnology, Cobalt Biomedicine, Kaleido Biosciences, Seres Therapeutics, and Axcella Health, each focused on advancing therapeutic development through cutting-edge science and technology. von Maltzahn's academic background includes a PhD in Biomedical Engineering and Medical Physics from the Massachusetts Institute of Technology, along with degrees in Bioengineering and Chemical Engineering.
This person is not in any offices
Indigo
22 followers
Indigo Ag improves farmer profitability, environmental sustainability, and consumer health through the use of nature-based and digital technologies. The company’s core offerings – Carbon, Market+, and biotrinsic – integrate across the supply chain to optimize how the world’s most impactful crops are produced, sourced, and distributed. Founded in 2014 with a mission of harnessing nature to help farmers sustainably feed the planet, today the company's technology connects stakeholders across the agricultural ecosystem to unlock sustainability and profitability benefits for all.